WO1997044063A3 - Dha-pharmaceutical agent conjugates - Google Patents

Dha-pharmaceutical agent conjugates Download PDF

Info

Publication number
WO1997044063A3
WO1997044063A3 PCT/US1997/008867 US9708867W WO9744063A3 WO 1997044063 A3 WO1997044063 A3 WO 1997044063A3 US 9708867 W US9708867 W US 9708867W WO 9744063 A3 WO9744063 A3 WO 9744063A3
Authority
WO
WIPO (PCT)
Prior art keywords
dha
pharmaceutical agent
agent conjugates
pharmaceutical agents
conjugates
Prior art date
Application number
PCT/US1997/008867
Other languages
French (fr)
Other versions
WO1997044063A2 (en
Inventor
Matthews O Bradley
Victor E Shashoua
Nigel L Webb
Charles S Swindell
Original Assignee
Neuromedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuromedica Inc filed Critical Neuromedica Inc
Priority to AT97926723T priority Critical patent/ATE273025T1/en
Priority to CA002255614A priority patent/CA2255614C/en
Priority to EP97926723A priority patent/EP0909183B1/en
Priority to AU31425/97A priority patent/AU725759B2/en
Priority to DE69730217T priority patent/DE69730217T2/en
Priority to JP54281197A priority patent/JP4402173B2/en
Publication of WO1997044063A2 publication Critical patent/WO1997044063A2/en
Publication of WO1997044063A3 publication Critical patent/WO1997044063A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)

Abstract

The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.
PCT/US1997/008867 1996-05-22 1997-05-22 Dha-pharmaceutical agent conjugates WO1997044063A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT97926723T ATE273025T1 (en) 1996-05-22 1997-05-22 DHA PHARMACEUTICAL PRODUCT CONJUGATES
CA002255614A CA2255614C (en) 1996-05-22 1997-05-22 Dha-pharmaceutical agent conjugates
EP97926723A EP0909183B1 (en) 1996-05-22 1997-05-22 Dha-pharmaceutical agent conjugates
AU31425/97A AU725759B2 (en) 1996-05-22 1997-05-22 DHA-pharmaceutical agent conjugates
DE69730217T DE69730217T2 (en) 1996-05-22 1997-05-22 DHA PHARMACEUTICAL PRODUCT CONJUGATE
JP54281197A JP4402173B2 (en) 1996-05-22 1997-05-22 DHA-drug complex

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/651,312 US5795909A (en) 1996-05-22 1996-05-22 DHA-pharmaceutical agent conjugates of taxanes
US08/651,312 1996-05-22

Publications (2)

Publication Number Publication Date
WO1997044063A2 WO1997044063A2 (en) 1997-11-27
WO1997044063A3 true WO1997044063A3 (en) 1998-02-26

Family

ID=24612392

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/008867 WO1997044063A2 (en) 1996-05-22 1997-05-22 Dha-pharmaceutical agent conjugates

Country Status (10)

Country Link
US (3) US5795909A (en)
EP (2) EP1466628A1 (en)
JP (1) JP4402173B2 (en)
AT (1) ATE273025T1 (en)
AU (1) AU725759B2 (en)
CA (1) CA2255614C (en)
DE (1) DE69730217T2 (en)
DK (1) DK0909183T3 (en)
ES (1) ES2222514T3 (en)
WO (1) WO1997044063A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same

Families Citing this family (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20030073642A1 (en) * 1993-02-22 2003-04-17 American Bioscience, Inc. Methods and formulations for delivery of pharmacologically active agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5972948A (en) * 1994-07-01 1999-10-26 Solvay Pharmaceuticals Gmbh Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
WO1997044026A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
KR100330373B1 (en) * 1996-05-28 2002-11-07 주식회사한국신약 Pharmaceutical composition for injection containing taxol
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
ATE251913T1 (en) 1997-05-21 2003-11-15 Univ Leland Stanford Junior COMPOSITION AND METHOD FOR DELAYING TRANSPORT THROUGH BIOLOGICAL MEMBRANES
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
CN1141089C (en) * 1997-09-17 2004-03-10 卫材株式会社 Antimicrobials
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
EP1029536B1 (en) * 1997-10-01 2007-11-28 Novadel Pharma Inc. Buccal non-polar spray
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
DE69922296T2 (en) * 1998-01-13 2005-10-27 Daiichi Suntory Pharma Co., Ltd. ANTIBACTERILLE COMPOSITION FOR TOPICAL APPLICATION, CONTAINING FAROPENEM
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
UA65607C2 (en) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Pharmaceutical composition (variants) and process for its preparation
FI980901A (en) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Oral compositions that controlled release the levosimendan
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
KR100634953B1 (en) * 1998-07-20 2006-10-17 스미스클라인 비참 코포레이션 Bioenhanced formulations comprising eprosartan in oral solid dosage form
CA2525555A1 (en) * 1998-07-28 2000-02-10 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
KR100396171B1 (en) * 1998-08-10 2003-08-27 아사히 가세이 가부시키가이샤 Sustained-release Oral Preparation of Fasudil hydrochloride
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
DE60039410D1 (en) * 1999-01-29 2008-08-21 Takeda Pharmaceutical COMPRESSION HAMMER WITH COATING TREATMENT
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
RU2001127313A (en) * 1999-03-09 2003-09-20 Протарга, Инк. (Us) CONJUGATES FATTY ACID-ANTI-CANCER AGENT AND THEIR APPLICATION
US6475984B2 (en) 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
ATE415969T1 (en) * 1999-05-07 2008-12-15 Wockhardt Ltd (S)-BENZOQUINOLICIN CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
US6197337B1 (en) * 1999-05-10 2001-03-06 Kenneth Weisman Therapeutic uses of abarelix
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
AU769315B2 (en) 1999-08-24 2004-01-22 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
JP2003508487A (en) * 1999-09-09 2003-03-04 イーエフエイ サイエンシーズ エルエルシー． Methods for treating cell proliferative disorders, including cancer
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US20020045606A1 (en) * 1999-12-02 2002-04-18 Reddy Satyanarayana G. Esters of vitamin D3 and uses thereof
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
US20020010140A1 (en) 2000-01-19 2002-01-24 Striker Gary E. Use of pentosan polysulfate to treat certain conditions of the prostate
CZ20013430A3 (en) * 2000-02-02 2002-04-17 Florida State University Research Foundation, Inc. Taxanes substituted in position C10 with ester group
CO5280224A1 (en) * 2000-02-02 2003-05-30 Univ Florida State Res Found SUBSTITUTED TAXANS WITH ESTER IN C7, USEFUL AS ANTITUMOR AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US6660750B2 (en) 2000-02-15 2003-12-09 University Of Iowa Research Foundation Flavopiridol methods and compositions for HIV therapy
US6452024B1 (en) 2000-02-22 2002-09-17 Chaichem Pharmaceuticals International Process for extraction and purification of paclitaxel from natural sources
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
AU2002222931A1 (en) 2000-07-19 2002-01-30 University Of Pittsburgh Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin a
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6884777B1 (en) 2000-11-14 2005-04-26 The Nemours Foundation Method for treating respiratory distress syndrome
ATE556706T1 (en) * 2001-03-23 2012-05-15 Luitpold Pharm Inc FAT ALCOHOL-DRUG CONJUGATES
EP1427407A4 (en) * 2001-03-23 2005-05-11 Luitpold Pharm Inc Fatty amine drug conjugates
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
CA2354471A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 ester substituted taxanes
CA2354486A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C7 ester substituted taxanes
SG129990A1 (en) * 2001-08-01 2007-03-20 Univ Florida State Res Found C10 ester substituted taxanes
SG125889A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C7 ester subsituted taxanes
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
KR20100097224A (en) * 2001-09-27 2010-09-02 라모트 앳 텔 아비브 유니버시티 리미티드 Conjugated anti-psychotic drugs and uses thereof
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
AU2004201240B2 (en) * 2001-09-27 2008-08-07 Bar Ilan University Conjugated Psychotropic Drugs and Uses Thereof
US6730667B2 (en) * 2001-11-26 2004-05-04 William R. Deagle Iontophoresis disc pain blocker
CA2466869C (en) * 2001-11-29 2010-01-19 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
ES2497716T3 (en) * 2002-01-04 2014-09-23 Sound Pharmaceuticals Incorporated Compositions for use in methods intended to treat hearing loss
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
CA2475092C (en) 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
AU2003213682C1 (en) * 2002-03-04 2008-06-12 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
AU2003235931A1 (en) * 2002-05-13 2003-11-11 Takata Seiyaku Co., Ltd. Vintoperol-containing medicinal composition for transdermal administration
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040002663A1 (en) * 2002-06-26 2004-01-01 Reeves William H. Method and system for use in detecting a cancerous and precancerous pathology
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004033478A2 (en) * 2002-10-08 2004-04-22 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
EA200500804A1 (en) * 2002-12-10 2005-12-29 Биосинексус Инкорпорейтед Topical Anti-infective Compositions
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US6759539B1 (en) 2003-02-27 2004-07-06 Chaichem Pharmaceuticals International Process for isolation and purification of paclitaxel from natural sources
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
WO2004093807A2 (en) * 2003-04-22 2004-11-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatin vectors
NZ542342A (en) 2003-04-25 2009-05-31 Gilead Sciences Inc Antiviral phosphonate analogs
WO2005001041A2 (en) * 2003-05-28 2005-01-06 Paul Anziano Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
CA2532807A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
GB2423927A (en) * 2003-08-29 2006-09-13 Cotherix Inc Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
DE602004027936D1 (en) * 2003-10-29 2010-08-12 Sonus Pharmaceutical Inc TOCOPHEROL-MODIFIED THERAPEUTIC DRUG COMPOUND
US20080045559A1 (en) * 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CN1901901B (en) * 2003-10-30 2012-07-04 纽约州州立大学研究基金会 Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
GB0326180D0 (en) * 2003-11-11 2003-12-17 Leuven K U Res & Dev Biocompatible coating of medical devices
HN2005000054A (en) 2004-02-13 2009-02-18 Florida State University Foundation Inc REPLACED TAXANS WITH CYCLOPENTILO ESTERS IN C10
AR048078A1 (en) 2004-03-05 2006-03-29 Univ Florida State Res Found TAXANOS WITH SUBSTITUTE LACTILOXILO IN C7
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
WO2005094322A2 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413729D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
PL1791904T3 (en) * 2004-09-24 2015-02-27 Univ Maryland Method of treating organophosphorous poisoning
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
AU2006212738B2 (en) 2005-02-09 2012-04-05 Mitotek, Llc Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
CA2600134A1 (en) * 2005-03-08 2006-09-14 Sound Pharmaceuticals Incorporated Methods and compositions for treating cancer
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
EP1888727B1 (en) 2005-05-04 2015-04-15 Pronova BioPharma Norge AS New dha derivatives and their use as medicaments
JP5284779B2 (en) * 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド Novel salts of conjugated psychotropic drugs and methods for their preparation
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
CN1870631B (en) * 2005-11-11 2010-04-14 华为技术有限公司 Gate control method of media gateway
CA2635496A1 (en) * 2005-11-14 2007-05-24 Peter D. Winch Novel colored solutions of injectable drugs and their pharmaceutically acceptable salts
CA2632149C (en) * 2005-12-01 2011-11-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
CZ300305B6 (en) * 2005-12-20 2009-04-15 Heaton, A. S. Pharmaceutical composition containing taxane derivative and exhibiting enhanced therapeutic efficiency
JP2009533420A (en) * 2006-04-13 2009-09-17 アクテリオン ファーマシューティカルズ リミテッド Treatment of early idiopathic pulmonary fibrosis
EP2015632B1 (en) * 2006-04-19 2015-12-02 Mist Pharmaceuticals, LLC Stable hydroalcoholic oral spray formulations and methods
NZ572368A (en) * 2006-05-16 2011-04-29 Gilead Sciences Inc Method and compositions for treating hematological malignancies
FR2902659A1 (en) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa DHA ESTER AND ITS USE IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
AU2007274583B2 (en) 2006-07-17 2012-11-01 Bar-Ilan University Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders
US20080248135A1 (en) * 2006-07-28 2008-10-09 Collegium Pharmaceutical, Inc. Combination Therapy for Otitis with Antiseptic and pH Adjustment
WO2008021242A2 (en) * 2006-08-10 2008-02-21 The Research Foundation Of State University Of New York Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
CN101535238A (en) 2006-11-01 2009-09-16 普罗诺瓦生物医药挪威公司 Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR)
CA2673435C (en) * 2006-12-21 2012-10-09 Pfizer Products Inc. Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline
CA2673049C (en) * 2006-12-22 2016-02-23 Novadel Pharma Inc. Stable anti-nausea oral spray formulations and methods
CA2674367A1 (en) * 2007-01-03 2008-07-17 Glenn V. Cornett Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
TWI384986B (en) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same
US20100093749A1 (en) * 2007-03-09 2010-04-15 Novartis Ag Compounds
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
CN101801346A (en) * 2007-05-10 2010-08-11 诺瓦德尔药品公司 anti-insomnia compositions and methods
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance
EP3495369B1 (en) * 2007-06-13 2021-10-27 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
US8067632B2 (en) 2007-07-26 2011-11-29 The Board Of Trustees Of The Leland Stanford Junior University Process to produce prostratin and structural or functional analogs thereof
KR20100072230A (en) * 2007-09-26 2010-06-30 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 Azacytidine analogues and uses thereof
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
CN101328159B (en) * 2007-11-05 2011-12-21 孙汉翔 Taxone precursor anti-cancer drugs, medicinal composition and use thereof
CA2709219A1 (en) * 2007-12-12 2009-06-18 Ultimorphix Technologies B.V. Solid forms of tenofovir disoproxil
UY31531A1 (en) * 2007-12-17 2009-08-03 SALTS DERIVED FROM 8-OXOADENINE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THERAPY AS TOLL TYPE RECEIVER MODULATORS (TLR)
WO2009101616A1 (en) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
US8242166B2 (en) 2008-03-31 2012-08-14 Florida State University Research Foundation, Inc. C(10) ethyl ester and C(10) cyclopropyl ester substituted taxanes
WO2009126401A1 (en) * 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
NZ589883A (en) * 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
WO2010005986A1 (en) 2008-07-08 2010-01-14 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
ES2656903T3 (en) 2008-07-08 2018-02-28 Catabasis Pharmaceuticals, Inc. Acetylated fatty acid salicylates and their uses
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
ES2820857T3 (en) * 2008-12-01 2021-04-22 Oyster Point Pharma Inc Synthesis and novel salt forms of (R) -5 - ((E) -2-pyrrolidin-3-ylvinyl) pyrimidine
US20110268699A1 (en) * 2008-12-11 2011-11-03 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
DK2676953T3 (en) * 2008-12-18 2017-07-03 Novartis Ag Hemifumarate salt of 1- [4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl] -acetidine-3-carboxylic acid for use in the treatment of lymphocyte-mediated diseases
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) * 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
ES2788298T3 (en) * 2009-04-10 2020-10-21 Abraxis Bioscience Llc Nanoparticle formulations and their uses
TWI546537B (en) * 2009-05-19 2016-08-21 維維亞生技公司 Methods for providing personalized medicine tests ex vivo for hematological neoplasms
MX2011012262A (en) 2009-05-22 2012-01-25 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors.
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
BR112012013639A2 (en) 2009-12-09 2017-04-04 Bar-Ilan Univ "methods to improve cognitive functions"
WO2011085211A1 (en) 2010-01-08 2011-07-14 Catabasis Pharmaceuticals, Inc. Fatty acid fumarate derivatives and their uses
SI3354652T1 (en) 2010-03-10 2020-08-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
SG10201910912TA (en) 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
BR112013012502A2 (en) 2010-11-19 2019-03-06 Incyte Corporation substituted cyclobutyl pyrrolopyridine and derivative pyrrolopyrimidine derivatives as jak inhibitors
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2012154554A1 (en) * 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN102952138B (en) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 The salt of a kind of pyrazolopyrimidinone compound, polymorph and pharmaceutical composition, preparation method and application
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
US20130071477A1 (en) 2011-09-19 2013-03-21 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
CN104603096A (en) * 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
EA030705B1 (en) 2013-03-06 2018-09-28 Инсайт Холдингс Корпорейшн Processes and intermediates for making a jak inhibitor
ES2792549T3 (en) 2013-08-07 2020-11-11 Incyte Corp Sustained-release dosage forms for a JAK1 inhibitor
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
DK3157936T3 (en) 2014-06-18 2019-02-04 Thetis Pharmaceuticals Llc MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CN104225615B (en) * 2014-09-24 2017-02-01 东南大学 Taxol phospholipids compound, medicine composition and application thereof
WO2016198971A1 (en) * 2015-06-08 2016-12-15 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
US20190125702A1 (en) * 2016-03-15 2019-05-02 Vitality Biopharma, Inc. Methods and Compositions for the Treatment of Demyelinating Disorders
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
SI3661937T1 (en) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
PL3746429T3 (en) 2018-01-30 2022-06-20 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
WO2019191684A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
JP2021522186A (en) * 2018-04-17 2021-08-30 カーデュリオン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニーＣａｒｄｕｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， ＬＬＣ Thienopyrimidine meglumine salt
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
WO2020018888A1 (en) 2018-07-20 2020-01-23 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
EP3941897A4 (en) * 2019-03-22 2023-04-05 Integrated Nanotherapeutics Inc. Lipid conjugate prepared from scaffold moiety
KR20220107213A (en) 2019-11-22 2022-08-02 인사이트 코포레이션 Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007938A1 (en) * 1988-02-26 1989-09-08 Shashoua Victor E Fatty acid-drug conjugate for delivery of the drug across the blood-brain barrier
WO1992020362A1 (en) * 1991-05-14 1992-11-26 Shashoua Victor E Nerve growth peptides and uses therefor
WO1994012530A1 (en) * 1992-11-30 1994-06-09 Biosignal Kutató Fejlesztó Kft. Polyunsaturated fatty acyl-peptide composition
WO1996004001A1 (en) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
WO1996021658A1 (en) * 1995-01-09 1996-07-18 The Liposome Company, Inc. Hydrophobic taxane derivatives
WO1997044026A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
WO1997044336A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Conjugates of cis-docosahexaenoic acid and paclitaxel

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US449A (en) * 1837-11-11 Improvement in the mode of preparing paint for the protection of buildings against fire
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621048A (en) 1968-03-14 1971-11-16 Colgate Palmolive Co Quaternary ammonium compounds
US4218234A (en) 1972-12-07 1980-08-19 Novex Rt. Soil conditioners
SU477159A1 (en) 1973-07-27 1975-07-15 Всесоюзный научно-исследовательский институт фитопатологии Method for producing carboxylic acid amidophosphoryloxyethylamides
JPS5186479A (en) 1975-01-22 1976-07-29 Asahi Chemical Ind 55 furuororashirujudotainoseizohoho
DE2602175B2 (en) 1975-01-22 1978-05-03 Asahi Kasei Kogyo K.K., Osaka (Japan) 1-Alkanoyl-5-fluorouracil derivatives and their use
US4097597A (en) 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
US4351831A (en) 1977-11-02 1982-09-28 Massachusetts Institute Of Technology Process and composition for treating disorders by administering isoxsurpine and choline
US4287184A (en) 1977-11-23 1981-09-01 The Massachusetts General Hospital Process for healing wounds
US4185095A (en) 1977-11-23 1980-01-22 The Massachusetts General Hospital Nerve growth factor
US4407744A (en) 1977-11-23 1983-10-04 Young David M Process for obtaining nerve growth factor
JPS5553208A (en) 1978-10-13 1980-04-18 Mitsubishi Chem Ind Ltd Insecticide
IT7927748A0 (en) * 1979-11-30 1979-11-30 Simes DERIVATIVES OF 6,6'-PSYCAROTENEDIOIC ACID AND RELATED PREPARATION PROCEDURES.
US4346085A (en) * 1980-02-29 1982-08-24 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
US4636494A (en) * 1981-01-30 1987-01-13 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
JPS58177953A (en) * 1982-04-13 1983-10-18 Eisai Co Ltd Polyprenylcarboxylic acid amide and its preparation
JPS5925327A (en) 1982-07-31 1984-02-09 Hidematsu Hirai Preparation of antitumor complex
US4558049A (en) 1982-11-24 1985-12-10 Farmitalia Carlo Erba S.P.A. Antipsycotic benzoxazines
US5169762A (en) 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
JPS59204175A (en) 1983-04-28 1984-11-19 Terumo Corp 5-fluorouracil derivative, inhibitor of blood platelet aggregation using it, and preventive for cancer metastasis using it
WO1985001729A1 (en) * 1983-10-20 1985-04-25 Terumo Kabushiki Kaisha 5-fluorouracil derivatives and medicinal preparation containing same
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
US4684646A (en) * 1984-06-26 1987-08-04 Merck & Co., Inc. 2-acylaminomethyl-1,4-benzodiazepine derivatives as CCK-antagonists
US4868161A (en) 1984-06-29 1989-09-19 City Of Hope Method for promoting nerve regeneration
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4554272A (en) * 1985-01-25 1985-11-19 Merck & Co., Inc. Substituted quinazolino-1,4-benzodiazepin-6,9-diones and their preparation
US6448392B1 (en) * 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4729989A (en) 1985-06-28 1988-03-08 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4692441A (en) 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US5246726A (en) 1986-03-21 1993-09-21 Efamol Ltd. Iron-containing composition and method for treatment of cancer
FR2601676B1 (en) * 1986-07-17 1988-09-23 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF TAXOL AND DESACETYL-10 TAXOL
FR2601675B1 (en) * 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5459256A (en) 1987-04-17 1995-10-17 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Lipophilic, aminohydrolase-activated prodrugs
SE8703625D0 (en) 1987-09-18 1987-09-18 Kabivitrum Ab NEW MEDICAL USE
AU2526188A (en) 1987-09-22 1989-04-18 Regents Of The University Of California, The Liposomal nucleoside analogues for treating aids
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5420276A (en) 1987-11-03 1995-05-30 Abbott Laboratories Analogs of oxetanyl purines and pyrimidines
JPH01153629A (en) 1987-12-11 1989-06-15 Nippon Oil & Fats Co Ltd Anticancer agent
JPH01203331A (en) 1988-02-05 1989-08-16 Rikagaku Kenkyusho Carcinostatic agent
US6107499A (en) 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4933324A (en) * 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US5284876A (en) 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
JPH01287022A (en) 1988-05-12 1989-11-17 Nippon Oil & Fats Co Ltd Agent for conquering resistance to carcinostatic agent
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
JP2612619B2 (en) 1988-12-14 1997-05-21 財団法人相模中央化学研究所 Transdermal absorption enhancer consisting of phosphorus-containing compound
CH676909A5 (en) 1988-12-23 1991-03-28 Nestle Sa
HU207287B (en) 1989-01-17 1993-03-29 Biosignal Kutato Fejlesztoe Kf Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
GB8918294D0 (en) 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
JPH03236315A (en) 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd Antipsychotic agent
GB9001121D0 (en) 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5545719A (en) 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
JP2800953B2 (en) 1990-07-06 1998-09-21 住友製薬株式会社 New imide derivatives
US5169764A (en) 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
JP3139777B2 (en) 1990-08-27 2001-03-05 フマキラー株式会社 Recombinant mite allergen
US5059699A (en) 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
MX9102128A (en) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa DERIVATIVES OF TAXANE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
US5369191A (en) * 1992-01-23 1994-11-29 Kureha Kagaku Kogyo K.K. Aromatic thioether ketone/thioether sulfone copolymer and production process thereof
IT1254515B (en) * 1992-03-06 1995-09-25 Indena Spa TASSANI OF ONCOLOGICAL INTEREST, THEIR METHOD OF PREPARATION AND USE
IT1254517B (en) * 1992-03-06 1995-09-25 Indena Spa 14-BETA IDROSSI-10-DEACETIL-BACCATINA III, ITS DERIVATIVES, THEIR PREPATION AND THERAPEUTIC USE
US5214062A (en) 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
JPH0616548A (en) 1992-06-30 1994-01-25 Sagami Chem Res Center Tissue abnormal growth inhibitor
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
DE4224737A1 (en) 1992-07-27 1994-02-03 Herbert Prof Dr Schott New cytosine analogues with lipophilic protected amino gps. - for treatment of cancer and virus diseases e.g. AIDS, are more protected against enzymatic des-amination and can be used in higher doses than unprotected cpds.
US5352596A (en) 1992-09-11 1994-10-04 The United States Of America As Represented By The Secretary Of Agriculture Pseudorabies virus deletion mutants involving the EPO and LLT genes
US5453521A (en) * 1992-10-05 1995-09-26 Rhone-Poulenc Rorer S.A. Process for obtaining 10-deacetylbaccatin III
FR2696461B1 (en) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa New derivatives of taxol analogs, their preparation and compositions containing them.
US5356928A (en) * 1992-11-06 1994-10-18 Hauser Chemical Research, Inc. Cytotoxic agents
FR2697841B1 (en) * 1992-11-12 1995-01-13 Rhone Poulenc Rorer Sa New taxane derivatives, their preparation and the pharmaceutical compositions containing them.
FR2698269B1 (en) 1992-11-24 1995-01-06 Inst Nat Sante Rech Med New drugs based on unsaturated fatty acids, usable in particular as antiplatelet agents and / or as preferred transporters to the brain.
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US5496714A (en) 1992-12-09 1996-03-05 New England Biolabs, Inc. Modification of protein by use of a controllable interveining protein sequence
FR2698871B1 (en) * 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa New taxoids, their preparation and the pharmaceutical compositions containing them.
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
GB9301629D0 (en) 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
GB9304746D0 (en) 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5336684A (en) * 1993-04-26 1994-08-09 Hauser Chemical Research, Inc. Oxidation products of cephalomannine
FR2707293A1 (en) * 1993-07-08 1995-01-13 Rhone Poulenc Rorer Sa New taxoids, their preparation and pharmaceutical compositions containing them.
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
FR2712288B1 (en) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa New taxoids, their preparation and the pharmaceutical compositions containing them.
FR2712289B1 (en) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa New taxicin derivatives, their preparation and the pharmaceutical compositions containing them.
US5480799A (en) 1993-12-10 1996-01-02 The University Of North Carolina At Chapel Hill Sperm antigen corresponding to a sperm zona binding protein autoantigenic epitope
IT1264987B1 (en) 1993-12-14 1996-10-17 Prospa Bv SALTS OF A POLYUNSATURATED FATTY ACID AND PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604198A (en) 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
FR2721023B1 (en) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa New Taxoids, their preparation and the pharmaceutical compositions containing them.
JPH0815133A (en) 1994-06-29 1996-01-19 Hitachi Ltd Analytic element
FR2721928A1 (en) * 1994-07-04 1996-01-05 Rhone Poulenc Rorer Sa NOVEL TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5597719A (en) 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
JPH0827010A (en) 1994-07-19 1996-01-30 Nichinichi Seiyaku Kk Carcinostatic immunotherapeutic agent
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
JPH08163991A (en) 1994-12-15 1996-06-25 Mitsui Petrochem Ind Ltd Production of taxane-type diterpene
RU2166512C2 (en) 1995-01-16 2001-05-10 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Conjugates of therapeutic compound with fatty acid
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
US5532374A (en) 1995-06-06 1996-07-02 Hitachi Chemical Company, Ltd. Method of preparation of bis-quinolines
JPH0925231A (en) 1995-07-13 1997-01-28 Sagami Chem Res Center Metastasis-controlling agent
JPH0930963A (en) 1995-07-21 1997-02-04 Nisshin Oil Mills Ltd:The Medical oil and fat-containing composition
US5952317A (en) 1995-09-21 1999-09-14 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US5976784A (en) 1996-09-20 1999-11-02 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
JPH10168047A (en) 1996-12-04 1998-06-23 Kao Corp Amido derivative and amido derivative-containing composition for external application
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5955459A (en) 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US6184164B1 (en) * 1999-04-28 2001-02-06 The University Of Houston Bimodal silicon nitride-bas ceramic composites
US6459645B2 (en) 1999-09-30 2002-10-01 Intel Corporation VPX bank architecture

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007938A1 (en) * 1988-02-26 1989-09-08 Shashoua Victor E Fatty acid-drug conjugate for delivery of the drug across the blood-brain barrier
WO1992020362A1 (en) * 1991-05-14 1992-11-26 Shashoua Victor E Nerve growth peptides and uses therefor
WO1994012530A1 (en) * 1992-11-30 1994-06-09 Biosignal Kutató Fejlesztó Kft. Polyunsaturated fatty acyl-peptide composition
WO1996004001A1 (en) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
WO1996021658A1 (en) * 1995-01-09 1996-07-18 The Liposome Company, Inc. Hydrophobic taxane derivatives
WO1997044026A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
WO1997044336A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Conjugates of cis-docosahexaenoic acid and paclitaxel

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same

Also Published As

Publication number Publication date
AU725759B2 (en) 2000-10-19
US5795909A (en) 1998-08-18
US7199151B2 (en) 2007-04-03
ES2222514T3 (en) 2005-02-01
DE69730217D1 (en) 2004-09-16
EP0909183A2 (en) 1999-04-21
AU3142597A (en) 1997-12-09
ATE273025T1 (en) 2004-08-15
US20020010208A1 (en) 2002-01-24
CA2255614C (en) 2009-12-15
EP0909183B1 (en) 2004-08-11
DK0909183T3 (en) 2004-12-20
CA2255614A1 (en) 1997-11-27
US6602902B2 (en) 2003-08-05
US20040180949A1 (en) 2004-09-16
JP4402173B2 (en) 2010-01-20
WO1997044063A2 (en) 1997-11-27
EP1466628A1 (en) 2004-10-13
DE69730217T2 (en) 2005-07-28
JP2000514405A (en) 2000-10-31

Similar Documents

Publication Publication Date Title
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
EP0650370A4 (en) Methods and compositions for targeting specific tissue.
CA2310850A1 (en) A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia
DE69638351D1 (en) AS WELL AS FOR RESISTING THE DISTAL AND FRONT FEMUR
HUP0004421A3 (en) Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
ZA951292B (en) 4-amino derivatives of mycophenolic acid
AU2212299A (en) Compositions and methods for the treatment of tumor
IL134682A0 (en) Poly (adp-ribose) polymerase ("parp") inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
WO1999004752A3 (en) Methods for treating skin pigmentation
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
GB9923076D0 (en) Sapogenin derivatives and their use
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
AU2470299A (en) Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
HK1019205A1 (en) Galenic preparation for prevention and treatment of hepatocarcinoma.
HK1030144A1 (en) Method for treatment of liver tumours and pharmaceutical compositions for use therein.
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
AU2821295A (en) Compositions and methods for the treatment of tumors
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
AU4608296A (en) Methods and compositions for treatment of solid tumors in vivo

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2255614

Country of ref document: CA

Ref country code: CA

Ref document number: 2255614

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997926723

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997926723

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997926723

Country of ref document: EP